Biography
Biography: Nitin Naik
Abstract
The global life sciences industry is witnessing a surge in Chief Executive Officer (CEO) confidence from US tax reforms, turbulent equity markets, and the strengthening global economy. The growth of the life sciences industry is boosted by healthcare digitization and democratization creating an explosion in patient data, the emergence of value based reimbursement models, and healthcare consumerism shifting the risk from payers to providers. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics enabled by digital connectivity is driving regulatory and commercial changes in many exciting ways for the industry. In this session hear about Frost and Sullivan’s perspective of how business models are changing to maximize growth in life science companies as they embrace the new trends and technology. Key takeaways include top 3 growth opportunities in the biopharmaceutical industry, perspectives from game changing companies on collaborative projects, impact on disruptive technology platforms and best practices for implementing new business models